References

References
Albanese, M.A. & Mitchell, S. (1993). Problem-based learning: A review of literature on its outcomes and implementation issues. Academic Medicine, 68(1), 52-81.
Albanese
1
52
68
Academic Medicine
1993
Altman, R.B. (2003). Genetic sequence data for pharmacogenom- ics. Current Opinion in Drug Discovery and Development6(3), 297-303.
Altman
3
297
6
Current Opinion in Drug Discovery and Development
2003
Evans, W.E. & Johnson, J.A. (2001). Pharmacogenomics: The inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics, 2, 9-39.
Evans
9
2
Annual Review of Genomics and Human Genetics
2001
Gallagher, S. A., Sher, B.T., Stepien, WJ. & Workman, D. (1995). Implementing problem-based learning in science classrooms. School Science and Mathematics, 95(3), 136-146.
Gallagher
3
136
95
School Science and Mathematics
1995
Glasel, J.A. (2002). Drugs, the human genome, and individual- based medicine. Progress in Drug Research, 58, 1-50.
Glasel
1
58
Progress in Drug Research
2002
Issa, A.M. (2002). Ethical perspectives on pharmacogenomic pro- filing in the drug development process. Nature Reviews Drug Discovery, 1(4), 300-308.
Issa
4
300
1
Nature Reviews Drug Discovery
2002
Lazarou, J., Pomeranz, B.H. & Corey, P.N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta- analysis of prospective studies. Journal of the American Medical Association, 279(15), 1200-1205.
Lazarou
15
1200
279
Journal of the American Medical Association
1998
Mancinelli, L., Cronin, M. & Sadee, W. (2000). Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci2(1), 1- 13. Available online at: http://www.aapspharmsci.org/psO201/ ps020104/ps020104.pdf.
Mancinelli
1
1
2
AAPS PharmSci
2000
McLeod, H.L. & Evans, W.E. (2001). Pharmacogenomics: Unlocking the human genome for better drug therapy. Annual Review of Pharmacology and Toxicology, 41, 101-121.
McLeod
101
41
Annual Review of Pharmacology and Toxicology
2001
Merck & Co. (2003). The Merck Manual of Diagnosis and Therapy, Section 22, Chapter 302, Drug Toxicity. Available online at: http://www.merck.com/pubs/mmanual/section22/chapter 302/302b.htm.
National Center for Biotechnology Information. (2003). Single Nucleotide Polymorphism. Available online at: http://www. ncbi.nlm.nih.gov/SNP/snp_summary.cgi.
Roden, D.M. & George Jr., A.L. (2002). The genetic basis of vari- ability in drug responses. Nature Reviews Drug Discovery, 1(1), 37-44.
Roden
1
37
1
Nature Reviews Drug Discovery
2002
Roses, A.D. (2002). Genome-based pharmacogenetics and the pharmaceutical industry. Nature Reviews Drug Discovery, 1(7), 541-549.
Roses
7
541
1
Nature Reviews Drug Discovery
2002
Rothstein, M.A. & Epps, P.G. (2001). Ethical and legal implications of pharmacogenomics. Nature Reviews Genetics, 2(3), 228-231.
Rothstein
3
228
2
Nature Reviews Genetics
2001
Snedden, R. (1999). Pharmacogenetics. Paper for Wellcome Trust's Workshop on Pharmacogenetics, on October 29, 1999. Available online at: http://www.wellcome.ac.uk/en/imagesZ pharmacogenetics workshop_2438.pdf.
Snedden
Pharmacogenetics
Wellcome Trust's Workshop on Pharmacogenetics, on October 29, 1999
1999
Tufts Center for the Study of Drug Development. (2003). Total cost to develop a new prescription drug, including cost of post- approval research, is $897 million. Available online at: http:// csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=29.
This content is only available via PDF.

Article PDF first page preview

Article PDF first page preview